Ahead of this year's Prescription Drug User Fee Act (PDUFA) reauthorization, ACCC and 88 other patient and provider advocacy organizations urged congressional leadership to pass legislation that would improve the diversity of enrollment in clinical trials. The letter expresses support for a number of policy proposals, including provisions from the DIVERSE Trials Act (H.R. 5030/S. 2706) and the DEPICT Act (H.R.6584).
